XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous therapy ...
Grifols said on Monday it is considering a buy offer from the Catalan family and Canadian investment firm Brookfield which would delist it from the Spanish and Nasdaq stock markets, according to multiple media outlets. The deal is potentially worth around $6 billion based on the current market value.
July 4 (Reuters) - Spanish drugmaker Grifols (GRLS.MC), opens new tab has appointed Rahul Srinivasan as chief financial officer, the company said on Thursday, as the company reshuffles management after a short-seller fund questioned its accounting.
LONDON/MADRID, July 2 (Reuters) - Scranton Enterprises, an entity tied to the Grifols family, said on Tuesday it has reached an agreement with a private investor to refinance 377 million euros ($404.5 million) in debt of one of its units.
Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as...
With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China’s healthcare systemThrough a...
With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and marketing...
Grifols Partnership has received four CDMO Leadership Awards in 2024
POMPANO BEACH, Fla., April 8, 2024 /PRNewswire/ -- International Medical Industries, Inc. (IMI) is thrilled to announce an innovative partnership with Grifols that promises to enhance medication safety through cutting-edge technology. IMI, the industry leader in secure drug delivery devices, is joining forces with Kiro Grifols, dedicated to the state-of-the-art automated pharmacy compounding device (PCD), KIRO Fill. This strategic alliance aims to ensure the utmost security and integrity of compounded medications by combining the KIRO Fill with IMI's industry-leading Tamper Evident Caps.
Grifols™ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in...